Western Star Resources has acquired 14 new mining claims and secured a surface use agreement covering 640 acres at its Eagle Point Tungsten Project in New Mexico. This expansion includes historical trenches and extends the mineralized skarn system, supporting long-term development with exclusive surface rights for up to 25 years. The company is advancing exploration with an expanded UAV magnetic survey and plans detailed mapping, sampling, and permitting work. This move strengthens Western Star's position to develop a U.S. source of critical tungsten amid growing demand for domestic supply.
Western Star's expansion of the Eagle Point Tungsten Project provides context for readers interested in mining developments. For readers following Basic Materials-sector US stocks on Pluang, here is a market snapshot as of Sep 15, 2026 19:13 WIB: out of 32 stocks, 12 rose and 18 fell. Amcor PLC (AMCR) rose by 0.50% to USD 42.46, Standard Lithium Ltd (SLI) increased by 0.48% to USD 2.10, while Freeport-McMoRan Inc (FCX) declined by 0.48% to USD 69.02.
Vereigen Media's Verified Content Engagement (VCE) solution won Gold at the 2026 TITAN Business Awards for improving B2B lead quality through first-party data, human verification, and engagement validation. This approach helps marketing teams deliver...
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...
Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...
On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at pr...
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
